Detalhe da pesquisa
1.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
2.
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Blood
; 139(3): 413-423, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570876
3.
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.
Br J Clin Pharmacol
; 88(2): 836-841, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196037
4.
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Invest New Drugs
; 39(4): 1099-1105, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33683501
5.
A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
Eur J Haematol
; 106(2): 294-297, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33089525
6.
Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.
Br J Haematol
; 186(6): 845-854, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31177537
7.
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
Cancer
; 124(15): 3192-3200, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29797667
8.
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Blood
; 127(20): 2411-5, 2016 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26968534
9.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Blood
; 126(6): 739-45, 2015 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26059948
10.
SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
Haematologica
; 102(11): 1890-1900, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838991
11.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
N Engl J Med
; 369(6): 507-16, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782157
12.
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.
Blood
; 123(9): 1302-8, 2014 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24381226
13.
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
Blood
; 123(22): 3398-405, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24615778
14.
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
Blood
; 123(22): 3406-13, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24615776
15.
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Blood
; 123(22): 3390-7, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24615777
16.
Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies.
Haematologica
; 106(7): 2022-2025, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33504141
17.
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.
Br J Haematol
; 168(1): 38-45, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25146490
18.
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
J Pharmacol Exp Ther
; 344(2): 378-87, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23220742
19.
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Blood Cancer J
; 13(1): 9, 2023 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36631449
20.
Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia.
Blood Adv
; 7(17): 4728-4737, 2023 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36516082